LENZ Therapeutics Inc
LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Thera… Read more
LENZ Therapeutics Inc (LENZ) - Total Liabilities
Latest total liabilities as of September 2025: $16.78 Million USD
Based on the latest financial reports, LENZ Therapeutics Inc (LENZ) has total liabilities worth $16.78 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
LENZ Therapeutics Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how LENZ Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
LENZ Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of LENZ Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangdong Dp Co Ltd
SHE:300808
|
China | CN¥204.21 Million |
|
Dong Nai Port JSC
VN:PDN
|
Vietnam | ₫358.78 Billion |
|
John Wood Group PLC
PINK:WDGJF
|
USA | $4.45 Billion |
|
Shandong Zhangqiu Blower Co Ltd
SHE:002598
|
China | CN¥1.80 Billion |
|
LB Foster Company
NASDAQ:FSTR
|
USA | $155.10 Million |
|
Msscorps Co Ltd
TW:6830
|
Taiwan | NT$2.99 Billion |
|
Plan B Media PCL
BK:PLANB
|
Thailand | ฿6.88 Billion |
|
Talon Capital Corp. Class A Ordinary Shares
NASDAQ:TLNC
|
USA | $10.37 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down LENZ Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LENZ Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LENZ Therapeutics Inc (2019–2024)
The table below shows the annual total liabilities of LENZ Therapeutics Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $11.22 Million | -93.12% |
| 2023-12-31 | $163.09 Million | +129.31% |
| 2022-12-31 | $71.12 Million | +118.50% |
| 2021-12-31 | $32.55 Million | +0.57% |
| 2020-12-31 | $32.36 Million | +1355.22% |
| 2019-12-31 | $2.22 Million | -- |